BioGeometry Joins Hands with Sanyou to Build a New Generation AIGC-Driven Antibody Drug Discovery Platform

Both parties will create a next-generation AIGC-driven antibody drug discovery platform jointly and promote tripartite cooperation with significant innovative drug companies or biotech firms to enhance the efficiency of new drug R&D and help pharmaceutical R&D enterprises improve their global competitiveness.

Learn MoreBioGeometry Joins Hands with Sanyou to Build a New Generation AIGC-Driven Antibody Drug Discovery Platform

BioGeometry Announces Strategic Cooperation with Symary Biopharma for the Large Molecule Drug R&D

Both parties will fully leverage their respective strengths in a comprehensive strategic collaboration within the field of large molecule pharmaceuticals, aiming to achieve breakthrough progress in antibody drug R&D through the application of AI technology.

Learn MoreBioGeometry Announces Strategic Cooperation with Symary Biopharma for the Large Molecule Drug R&D